Security
TWST · Twist Bioscience Corp
TWSTNASDAQCommon stockCurrentCIK 1581280Updated Sep 27, 2026
TWST price & chart
Loading TradingView…
NASDAQ:TWST on TradingView ↗About the company
At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets. We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal - more experiments, more iterations, more chances for remarkable discoveries.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 641,861,000Source | 614,323,000Source | 776,403,000Source | 961,378,000Source |
| Property, Plant and Equipment, NetUSD | 102,283,000Source | 102,520,000Source | 131,830,000Source | 139,441,000Source |
| GoodwillUSD | 82,195,000Source | 85,811,000Source | 85,811,000Source | 85,811,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 183,049,000Source | 226,316,000Source | 286,470,000Source | 378,687,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 57,019,000Source | 34,903,000Source | 44,064,000Source | 40,294,000Source |
| Inventory, NetUSD | 28,309,000Source | 24,078,000Source | 32,063,000Source | 39,307,000Source |
| Assets, CurrentUSD | 332,966,000Source | 346,776,000Source | 424,256,000Source | 596,483,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 15,204,000Source | 11,396,000Source | 11,716,000Source | 11,914,000Source |
| Operating Lease, Right-of-Use AssetUSD | 49,377,000Source | 58,829,000Source | 71,531,000Source | 74,948,000Source |
| Other Assets, NoncurrentUSD | 4,902,000Source | 3,093,000Source | 5,681,000Source | 3,385,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 168,903,000Source | 141,634,000Source | 152,971,000Source | 171,993,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Additional Paid in CapitalUSD | 1,793,163,000Source | 1,715,119,000Source | 1,657,222,000Source | 1,619,644,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,319,578,000Source | -1,241,908,000Source | -1,033,034,000Source | -828,416,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -627,000Source | -522,000Source | -756,000Source | -1,843,000Source |
| Stockholders' Equity Attributable to ParentUSD | 472,958,000Source | 472,689,000Source | 623,432,000Source | 789,385,000Source |
| Liabilities and EquityUSD | 641,861,000Source | 614,323,000Source | 776,403,000Source | 961,378,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 91,406,000Source | 71,006,000Source | 73,323,000Source | 90,663,000Source |
| Operating Lease, Liability, CurrentUSD | 13,822,000Source | 14,805,000Source | 14,896,000Source | 13,642,000Source |
| Accounts Payable, CurrentUSD | 11,094,000Source | 1,630,000Source | 14,052,000Source | 20,092,000Source |
| Operating Lease, Liability, NoncurrentUSD | 61,750,000Source | 70,221,000Source | 79,173,000Source | 81,270,000Source |
| Other Liabilities, NoncurrentUSD | 747,000Source | 407,000Source | 475,000Source | 60,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 23,053,000Source | 15,104,000Source | 10,754,000Source | 10,169,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 336,400,000Source | 504,968,000Source |
| Deferred Revenue, CurrentUSD | 6,884,000Source | 2,131,000Source | 2,999,000Source | 3,476,000Source |
| Long-term Debt, Current MaturitiesUSD | — | — | — | 0Source |
| Short-term InvestmentsUSD | 49,385,000Source | 50,083,000Source | 49,943,000Source | 126,281,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -77,670,000Source | -208,726,000Source | -204,618,000Source | -217,863,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 24,853,000Source | 31,432,000Source | 29,310,000Source | 16,514,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 64,459,000Source | 50,925,000Source | 30,278,000Source | 79,664,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 22,382,000Source | -8,444,000Source | 4,320,000Source | 9,622,000Source |
| Increase (Decrease) in InventoriesUSD | 4,229,000Source | -7,986,000Source | -7,238,000Source | 7,536,000Source |
| Increase (Decrease) in Accounts PayableUSD | 9,332,000Source | -11,805,000Source | -2,508,000Source | 7,383,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | -11,177,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -47,628,000Source | -64,094,000Source | -142,474,000Source | -124,385,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | 0Source | 0Source | 8,160,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -24,762,000Source | -3,071,000Source | 50,612,000Source | -232,930,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 28,004,000Source | 5,076,000Source | 27,779,000Source | 101,857,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 28,540,000Source | 6,890,000Source | 911,000Source | 270,534,000Source |
| Repayments of Long-term DebtUSD | — | 0Source | 0Source | 1,558,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -43,707,000Source | -60,149,000Source | -90,978,000Source | -87,100,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 185,425,000Source | 229,132,000Source | 289,281,000Source | 380,259,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | 0Source | 0Source | 9,000Source |
| Income Taxes Paid, NetUSD | 683,000Source | 344,000Source | 420,000Source | 246,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 143,000Source | 126,000Source | -27,000Source | -319,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 64,459,000Source | 50,925,000Source | 30,278,000Source | 79,033,000Source |
| Amortization of Intangible AssetsUSD | 1,100,000Source | 4,100,000Source | 5,300,000Source | 4,900,000Source |
| Capitalized Computer Software, AmortizationUSD | 2,900,000Source | 2,600,000Source | — | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 336,400,000Source | 504,968,000Source |
| Deconsolidation, Gain (Loss), AmountUSD | — | 0Source | 0Source | 4,607,000Source |
| DepreciationUSD | 23,800,000Source | 27,300,000Source | — | — |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | 1,100,000Source | — | — | — |
| Gain (Loss) on Disposition of BusinessUSD | 48,847,000Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | 0Source | -44,930,000Source | -6,785,000Source | 0Source |
| GoodwillUSD | 82,195,000Source | 85,811,000Source | 85,811,000Source | 85,811,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | 4,475,000Source | 35,864,000Source | — | 0Source |
| Income Tax Expense (Benefit)USD | 719,000Source | 560,000Source | 1,152,000Source | -10,411,000Source |
| InterestExpenseNonoperatingUSD | — | 29,000Source | — | — |
| Investment Income, InterestUSD | 11,364,000Source | 15,344,000Source | 14,365,000Source | 3,062,000Source |
| Net Income (Loss) Attributable to ParentUSD | -77,670,000Source | -208,726,000Source | -204,618,000Source | -217,863,000Source |
| Operating Lease, ExpenseUSD | — | — | 16,200,000Source | 15,600,000Source |
| Operating Lease, Impairment LossUSD | -20,000Source | 940,000Source | 2,573,000Source | 20,127,000Source |
| Other Nonoperating Income (Expense)USD | -903,000Source | -2,650,000Source | -667,000Source | -1,087,000Source |
| Payments to Acquire InvestmentsUSD | 49,393,000Source | 51,905,000Source | 76,345,000Source | 217,639,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | 0Source |
| Restructuring CostsUSD | 0Source | 0Source | 16,169,000Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 376,572,000Source | 312,974,000Source | 245,109,000Source | 203,565,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 246,976,000Source | 218,398,000Source | 189,738,000Source | 212,949,000Source |
| Operating Income (Loss)USD | -136,259,000Source | -220,831,000Source | -217,159,000Source | -234,776,000Source |
| Other Nonoperating Income (Expense)USD | -903,000Source | -2,650,000Source | -667,000Source | -1,087,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -76,951,000Source | -208,166,000Source | -203,466,000Source | -228,274,000Source |
| Income Tax Expense (Benefit)USD | 719,000Source | 560,000Source | 1,152,000Source | -10,411,000Source |
| Net Income (Loss) Attributable to ParentUSD | -77,670,000Source | -208,726,000Source | -204,618,000Source | -217,863,000Source |
| Earnings Per Share, BasicUSD per share | -1.3Source | -3.6Source | -3.6Source | -4.04Source |
| Earnings Per Share, DilutedUSD per share | -1.3Source | -3.6Source | -3.6Source | -4.04Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 59,808,000Source | 58,016,000Source | 56,885,000Source | 53,885,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 59,808,000Source | 58,016,000Source | 56,885,000Source | 53,885,000Source |
| Interest Expense (non-operating)USD | — | 29,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 1,100,000Source | 4,100,000Source | 5,300,000Source | 4,900,000Source |
| Capitalized Computer Software, AmortizationUSD | 2,900,000Source | 2,600,000Source | — | — |
| Costs and ExpensesUSD | 512,831,000Source | 533,805,000Source | 462,268,000Source | 438,341,000Source |
| Current Income Tax Expense (Benefit)USD | 719,000Source | 560,000Source | 1,152,000Source | 766,000Source |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | 1,100,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -78,490,000Source | -209,545,000Source | -205,389,000Source | -231,659,000Source |
| Interest ExpenseUSD | — | — | 5,000Source | 80,000Source |
| Interest Income, OperatingUSD | 0Source | — | — | — |
| Investment Income, InterestUSD | 11,364,000Source | 15,344,000Source | 14,365,000Source | 3,062,000Source |
| Operating Lease, ExpenseUSD | — | — | 16,200,000Source | 15,600,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | 0Source |
| Research and Development ExpenseUSD | 80,285,000Source | 90,852,000Source | 106,894,000Source | 120,307,000Source |
| Restructuring CostsUSD | 0Source | 0Source | 16,169,000Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 376,572,000Source | 312,974,000Source | 245,109,000Source | 203,565,000Source |
Filing attachments
tm2622018d2_ex99-1.htm · 8-K · 2026-08-05
EX-99.1 4 tm2622018d2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock SOUTH SAN FRANCISCO, Calif. - August 4, 2026 - Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock. In addition, Twist intends to grant the underwriters a 30-day option to purchase up to…
Read attachment ↗tm2622018d2_ex99-2.htm · 8-K · 2026-08-05
EX-99.2 5 tm2622018d2_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif. - August 4, 2026 - Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock at a price to the public of $96.00 per share. All of the shares of common stock to be…
Read attachment ↗twst-2026630xex991.htm · 8-K · 2026-08-03
EX-99.1 2 twst-2026630xex991.htm EX-99.1 Document Exhibit 99.1 Twist Bioscience Reports Fiscal Third Quarter 2026 Financial Results - Record revenue of $118.4 million in 3QFY26; Increase of more than 23% over $96.1 million in 3QFY25; 14th consecutive quarter of sequential growth - - Gross margin of 52.8% in 3QFY26, sequential increase of 120 basis points - - FY 2026 Revenue guidance raised to $456-$457M, an increase of $12M at the midpoint; Reiterating Q4 FY26 Adj EBITDA breakeven - SO…
Read attachment ↗twst-2026331xex991.htm · 8-K · 2026-05-04
EX-99.1 2 twst-2026331xex991.htm EX-99.1 Document Exhibit 99.1 Twist Bioscience Reports Fiscal Second Quarter 2026 Financial Results - Record revenue of $110.7 million in 2QFY26; Increase of more than 19% over $92.8 million in 2QFY25; 13th consecutive quarter of sequential growth - - Gross margin of 51.6% in 2QFY26; Improvement of approximately 2 margin points versus 2QFY25 - - Revenue guidance raised to $442-$447M; Reiterating Q4 FY26 Adj EBITDA breakeven - SOUTH SAN FRANCISCO, Calif.…
Read attachment ↗tm266463d1_ex4-1.htm · 8-K · 2026-02-17
EX-4.1 2 tm266463d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 FORM OF REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated [●], 2026 (the “Agreement Effective Date”), is entered into by and among (i) Twist Bioscience Corporation, a Delaware corporation (the “Company”), and (ii) [●] (“Stockholder”). The Company and Stockholder may sometimes be referred herein individually as a “Party,” and collectively, as the “Parties.” Capitalized terms used but not defined i…
Read attachment ↗twst-20250930xex991.htm · 8-K · 2025-11-14
EX-99.1 2 twst-20250930xex991.htm EX-99.1 Document Exhibit 99.1 Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2025 Financial Results - Record revenue of $376.6 million in Fiscal 2025; Increase of 20% over $313.0 million in Fiscal 2024 - - Record revenue of $99.0 million in Q4FY25; Increase of 17% over $84.7 million in Q4FY24, 11th consecutive quarter of sequential growth - - Gross margin of 50.7% in FY25; Improvement of 8.1 margin points versus 42.6% in FY24 - SOU…
Read attachment ↗